Abnormal α-Synuclein Interactions with Rab Proteins in α-Synuclein A30P Transgenic Mice

Journal of Neuropathology and Experimental Neurology

Volumn 63, Issue 4, 2004, Pages 302-313

  Dalfo E ^a   Gomez Isla T ^c   Rosa, J L ^a   Nieto Bodelon M ^c   Cuadrado Tejedor, M ^c   Barrachina, M ^b   Ambrosio, S ^a   Ferrer, I ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); Parkinson disease; Rab3a; Rab5; Rab8; Rotenone; synuclein

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; DEOXYCHOLIC ACID; DIMETHYL SULFOXIDE; DODECYL SULFATE SODIUM; RAB PROTEIN; RAB8 PROTEIN; ROTENONE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN HOMOGENATE; BRAIN SLICE; CONTROLLED STUDY; DYSTONIA; EXOCYTOSIS; GENE MUTATION; GLIOSIS; GOLGI COMPLEX; HIPPOCAMPUS; MOLECULAR WEIGHT; MOUSE; NERVE CELL PLASTICITY; NEURITE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RIGIDITY; SYNAPSE; SYNAPSE VESICLE; TRANSGENIC MOUSE; TREMOR;

EID: 1842563080     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/63.4.302     Document Type: Article

References (58)

1. George JM, Jin H, Woods WS, Clayton DF. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995;15:361-72
2. Iwai A, Masliah E, Yoshimoto M, et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995;14:467-75
3. Withers GS, George JM, Banker GA, Clayton DF. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res Dev Brain Res 1997;99:87-94
4. Clayton DF, George JM. The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 1998;21:249-54
5. Lykkebo S, Jensen PH. Alpha-synuclein and presynaptic function. NeuroMolecular Med 2002;2:115-29
6. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-47
7. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-8
8. Polymeropoulos MH. Autosomal dominant Parkinson's disease and alpha-synuclein. Ann Neurol 1998;44:S63-S64
9. Goldberg MS, Lansbury PT. Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2000;2:115-19
10. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: Clinical and pathological implications. Arch Neurol 2001;58:186-90
11. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501
12. Goedert M. Parkinson's disease and other alpha-synucleinopathies. Clin Chem Lab Med 2001;39:308-12
13. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993;90:11282-86
14. Irizarry MC, Kim TW, McNamara M, et al. Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. J Neuropathol Exp Neurol 1996;55:889-95
15. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-40
16. Wakabayashi K, Matsumoto K, Takayama K, Yoshimoto M, Takahashi H. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett 1997;239:45-48
17. Gomez-Tortosa E, Newel K, Irizarry MC, Sanders JL, Hyman BT. Alpha-synuclein immunoreactivity in dementia with Lewy bodies: Morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol 2000;99:352-57
18. Giasson BI, Uryu K, Trojanowski JQ, Lee VM. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 1999;274:7619-22
19. Krishnan S, Chi EY, Wood SJ, et al. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease α-synuclein fibrillogenesis. Biochemistry 2003;42:829-37
20. Kahle PJ, Haas C, Kretzschmar HA, Neumann M. Structure/function of synuclein in health and disease: Rational development of animal models for Parkinson's and related diseases. J Neurochem 2002;82:449-57
21. Jellinger KA. Experimental models of synucleinopathies. In: Dickson D, ed. Neurodegeneration: The molecular pathology of dementia and movement disorders. Basel: ISN Neuropathol Press, 2003:215-23
22. Kahle PJ, Neumann M, Ozmen L, Haass C. Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein. Ann N Y Acad Sci 2000;920:33-41
23. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 2000;287:1265-69
24. van der Putten H, Wiederhold KH, et al. Neuropathology in mice expressing human alpha-synuclein. J Neurosci 2000;20:6021-29
25. Gomez-Isla T, Irizarry MC, Mariash A, et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol Aging 2003;24:245-58
26. Steidl JV, Gomez-Isla T, Mariash A, Ashe KH, Boland LM. Altered short-term hippocampal synaptic plasticity in mutant synuclein transgenic mice. Neuroreport 2003;14:219-23
27. Abeliovich A, Schmitz Y, Farinas I, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000;25:239-52
28. Cabin DE, Shimazu K, Murphy D, et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 2002;22:8797-8807
29. Zerial M, McBride H. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2001;2:107-17
30. Fischer von Mollard G, Stahl B, Li C, Südhof TC, Jahn R. Rab proteins in regulated exocytosis. Trends Biochem Sci 1994;19:164-68
31. Jahn R, Südhof TC. Synaptic vesicles and exocytosis. Annu Rev Neurosci 1994;17:219-46
32. Geppert M, Bolshakov VY, Siegelbaum SA, et al. The role of Rab3A in neurotransmitter release. Nature 1994;369:493-97
33. Nonet ML, Staunton JE, Kilgard MP, et al. Caenorhabditis elegans rab-3 mutant synapses exhibit impaired function and are partially depleted of vesicles. J Neurosci 1997;17:8061-73
34. Geppert M, Goda Y, Stevens CF, Südhof TC. The small GTP-binding protein Rab3A regulates a late step in synaptic vesicle fusion. Nature 1997;387:810-14
35. Geppert M, Südhof TC. Rab3 and synaptotagmin: The yin and yang of synaptic membrane fusion. Annu Rev Neurosci 1998;21:75-95
36. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1993;219:979-80
37. Przedborski S, Vila M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: A tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 2003;991:189-98
38. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-6
39. Dickson DW, Liu W, Hardy J, et al. Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 1999;155:1241-51
40. Gai WP, Pountney DL, Power JH, et al. Alpha-synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy. Exp Neurol 2003;181:68-78
41. Rosa JL, Casaroli-Marano RP, Buckler AJ, Vilaro S, Barbacid M. p619, a giant protein related to the chromosome condensation regulator RCC1, stimulates guanine nucleotide exchange on ARF1 and Rab proteins. Embo J 1996;15:4262-75
42. El-Agnaf OM, Jakes R, Curran MD, Wallace A. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett 1998;440:67-70
43. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998;4:1318-20
44. Kahle PJ, Neumann M, Ozmen L, et al. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 2001;159:2215-25
45. Conway KA, Harper JD, Lansbury PT. Fibrils formed in vitro from alpha-synuclein and two mutant linked to Parkinson's disease are typical amyloid. Biochemistry 2000;39:2552-63
46. Li J, Uversky VN, Fink AL. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein. Biochemistry 2001;40:11604-13
47. Kowal NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ. MPTP induces synuclein aggregation in the substantia nigra of baboons. NeuroReport 2000;11:211-13
48. Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurosci 2000;74:721-29
49. Sherere TH, Kim JH, Betarbet R, Greenamyre JT. Subcutaneus rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation. Exp Neurol 2002;179:9-16
50. Simons K, Zerial M. Rab proteins and the road maps for intracellular transport. Neuron 1993;11:789-99
51. Lledo PM, Johannes L, Vernier P, Zorec R, Darchen F, Vincent JD, Henry JP, Mason WT. Rab3 proteins: Key players in the control of exocytosis. Trends Neurosci 1994;17:426-32
52. Pfeffer SR. Rab GTPases: Master regulators of membrane trafficking. Curr Opin Cell Biol 1994;6:522-26
53. 2+/phospholipid-binding protein, depends on Rab3A/C. Neuron 1994;13:885-98
54. Shirataki H, Yamamoto T, Hagi S, et al. Rabphilin-3a is associated with synaptic vesicles in a manner independent of Rab3a. J Biol Chem 1994;269:32717-20
55. Lotharius J, Brundin P. Pathogenesis of Pakinson's disease: Dopamine, vesicles and α-synuclein. Nature Rev 2002;3:1-11
56. Lee M, Hyun D, Halliwell B, Jenner P. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 2001;76:998-1009
57. Tabrizi SJ, Orth M, Wilkinson JM, et al. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 2000;9:2683-89
58. Sung JY, Kim J, Paik SR, Park JH, Ahn YS, Chung KC. Induction of neuronal death by Rab5A-dependent endocytosis of synuclein. J Biol Chem 2001;276:27441-48